Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]) has a new chief scientific officer. Guriqbal Basi has been appointed to the post, where he will oversee the Cambridge, MA, company’s rare disease drug pipeline. Basi’s 30 years of pharmaceutical industry experience includes several leadership roles at the former Ireland-based drug company Elan, now part of Perrigo (NYSE: [[ticker:PRGO]]).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
